Brief: Moleculin Receives First Country Approval In Europe To Begin Recruiting For Phase 3 R/R Acute Myeloid Leukemia Trial
11/02/2025 13:52
Feb 11 (Reuters) - Moleculin Biotech MBRX.O :
* MOLECULIN RECEIVES FIRST COUNTRY APPROVAL IN EUROPE TO
BEGIN
RECRUITING FOR THE MIRACLE PHASE 3 R/R ACUTE MYELOID LEUKEMIA
(AML) PIVOTAL TRIAL
* MOLECULIN BIOTECH INC - FIRST SUBJECT TREATMENT IN MIRACLE
TRIAL
EXPECTED Q1 2025
Source text: ID:nPn7y6kN7a
Further company coverage: MBRX.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Moleculin Biotech
See all newsMoleculin Biotech Inc reports results for the quarter ended September 30 - Earnings Summary
Brief: Moleculin Secures Australian Patent For Annamycin Formulation Technology
Moleculin Biotech Inc expected to post a loss of $8.87 a share - Earnings Preview
Brief: Moleculin Biotech Completes Dosing In Part A Of Miracle Trial Data Readout On Track For Q1 2027
NASDAQ RESUMED AT 09:00 AM